CTOs on the Move


 
TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.tscan.com
  • 830 Winter Street
    Waltham, MA USA 02451
  • Phone: 857.399.9500

Executives

Name Title Contact Details
Justin McCue
Chief Technology Officer Profile

Funding

Tscan raised $35M on 01/10/2020

Similar Companies

Adarza BioSystems Inc

Adarza BioSystems, Inc. manufactures a label-free platform technology that enables the simultaneous detection of hundreds of analytes in a single drop of fluid.

F1 Oncology

We are harnessing the power of the immune system to target some of the most challenging solid tumor malignancies.

STIMIT

STIMIT`s proprietary technology enables extended local delivery of cancer immunotherapy in the context of tumor resection, the standard of care for most patients with solid tumors. Concentrating and retaining the action of potent immunomodulators locally dramatically improves the efficacy and safety of these compounds relative to administration in solution, whether via intravenous or even intratumoral injection.

Evozyne

Evozyne is a data-driven evolution-based molecular engineering platform for building novel, application-specific proteins with advanced functionality.

Akriveia Therapeutics

`Akrevia` is derived from the Greek word for `precision`, which reflects our mission to precisely deliver the activity of potent, tailored immunotherapies exactly where it’s needed.